Literature DB >> 29156504

Clinical risk reclassification at 10 years.

Nancy R Cook1, Olga V Demler1, Nina P Paynter1.   

Abstract

Three papers in this issue focus on the role of calibration in model fit statistics, including the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). This commentary reviews the development of such reclassification statistics along with more recent advances in our understanding of these measures. We show how the two-category NRI and the IDI are affected by changes in the event rate in theory and in an applied example. We also describe the role of calibration and how it may be assessed. Finally, we discuss the relevance of the event rate NRI for clinical use.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  calibration; clinical utility; reclassification

Mesh:

Substances:

Year:  2017        PMID: 29156504      PMCID: PMC5726289          DOI: 10.1002/sim.7340

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  30 in total

Review 1.  The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force.

Authors:  Jennifer S Lin; Carin M Olson; Eric S Johnson; Evelyn P Whitlock
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

2.  Interpreting incremental value of markers added to risk prediction models.

Authors:  Michael J Pencina; Ralph B D'Agostino; Karol M Pencina; A Cecile J W Janssens; Philip Greenland
Journal:  Am J Epidemiol       Date:  2012-08-08       Impact factor: 4.897

3.  Net reclassification improvement and integrated discrimination improvement require calibrated models: relevance from a marker and model perspective.

Authors:  Maarten J G Leening; Ewout W Steyerberg; Ben Van Calster; Ralph B D'Agostino; Michael J Pencina
Journal:  Stat Med       Date:  2014-08-30       Impact factor: 2.373

4.  What to expect from net reclassification improvement with three categories.

Authors:  Karol M Pencina; Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2014-08-31       Impact factor: 2.373

5.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

6.  Simpson's paradox in the integrated discrimination improvement.

Authors:  J Chipman; D Braun
Journal:  Stat Med       Date:  2016-01-05       Impact factor: 2.373

7.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

8.  Decision curve analysis: a novel method for evaluating prediction models.

Authors:  Andrew J Vickers; Elena B Elkin
Journal:  Med Decis Making       Date:  2006 Nov-Dec       Impact factor: 2.583

9.  Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

Review 10.  Net reclassification indices for evaluating risk prediction instruments: a critical review.

Authors:  Kathleen F Kerr; Zheyu Wang; Holly Janes; Robyn L McClelland; Bruce M Psaty; Margaret S Pepe
Journal:  Epidemiology       Date:  2014-01       Impact factor: 4.822

View more
  2 in total

1.  Quantifying the added value of new biomarkers: how and how not.

Authors:  Nancy R Cook
Journal:  Diagn Progn Res       Date:  2018-07-11

2.  Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction.

Authors:  Jodi D Edwards; Jeff S Healey; Jiming Fang; Kathy Yip; David J Gladstone
Journal:  J Am Heart Assoc       Date:  2020-05-20       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.